ClinicalTrials.gov
ClinicalTrials.gov Menu

SPM Regulation by Fish Oil Supplements in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03347006
Recruitment Status : Active, not recruiting
First Posted : November 20, 2017
Last Update Posted : June 11, 2018
Sponsor:
Collaborator:
Metagenics, Inc.
Information provided by (Responsible Party):
Queen Mary University of London

Brief Summary:
A randomised, double-blind, placebo-controlled study to determine whether fish oil supplementation regulates peripheral levels of specialized pro-resolving mediators and white blood cell responses in healthy volunteers

Condition or disease Intervention/treatment Phase
Healthy Volunteers Dietary Supplement: SPM Active Not Applicable

Detailed Description:

Rationale for the study The relationship between omega-3 essential fatty acid supplementation, and specifically fish oil supplementation, and SPM production in humans is very poorly understood. Given that the body produces SPM from omega-3 essential fatty acids to regulate inflammation and also to repair damaged tissues, it is critical to gain further insights on how the body utilizes dietary supplementation of omega-3 fatty acids from fish oils for SPM formation. With the availability of a mass spectrometry based platform developed by the investigators the scientific community is now in a unique position to better understand the biology of fish oil supplementation by monitoring the levels of SPM in plasma. This understanding may in turn shed light into the beneficial actions of omega-3 supplementation. It may also provide new leads for the control of excessive inflammation, as found in chronic inflammatory disorders, via dietary supplementation to exploit the body's own defense systems.

Rationale for choice of doses Given that in a study using a different fish oil source and formulation the investigators found that 1 g of essential fatty acids gave a mild but significant increase in plasma SPM levels (25) the investigators chose the lowest dose in the study to be of 1.5g. with the other two doses being within the European Food Safety Authority's Tolerable Upper Intake Level for supplements containing both EPA and DHA. Given that this limit is of 5 g and previous study with both healthy volunteers and patients demonstrated that doses up to 4 g are well tolerated (22-24), the investigators chose the remaining 2 doses to be 3.0 g and 4.5 g. In addition, this supplement was awarded a Generally Recognized as Safe Status (see appendix 1) in the for a dose of up to 5 g. Similar doses of the emulsion from of the fish oil supplement are also being used in an ongoing clinical study in the USA (ClinicalTrials.gov Identifier: NCT02719665) measuring different outcomes to those being investigated in the present study.

Aim of research The aim of this research is to investigate whether fish oil supplementation increases the peripheral blood levels of SPM and whether fish oil supplementation also regulates peripheral white blood cell responses (including neutrophils, monocytes and platelets) to inflammatory stimuli.

Original hypothesis Given that fish oils are rich in omega-3 essential fatty acids that are precursors in the biosynthesis of SPM the hypothesis underlying the present study is: Fish oil supplementation increase peripheral blood levels of SPM precursors that may be converted to bioactive mediators which in turn will regulate white blood cell responses.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: SPM Active is the supplement tested in this study
Masking: Double (Participant, Investigator)
Masking Description: Double blind placebo controlled
Primary Purpose: Basic Science
Official Title: Exploratory Double Blind Placebo Controlled Study Investigating the Regulation of Proresolving Mediators and White Blood Cell Responses by Fish Oil Supplements in Healthy Volunteers
Actual Study Start Date : March 20, 2017
Estimated Primary Completion Date : June 15, 2018
Estimated Study Completion Date : June 15, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Fish oil

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo control
Dietary Supplement: SPM Active

Supplement or placebo will be administered orally between 9 am to 9:30 am.

  • Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Experimental: Dose 1
1.5 g of omega-3 supplement
Dietary Supplement: SPM Active

Supplement or placebo will be administered orally between 9 am to 9:30 am.

  • Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Experimental: Dose 2
3.0 g of omega-3 supplement
Dietary Supplement: SPM Active

Supplement or placebo will be administered orally between 9 am to 9:30 am.

  • Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Experimental: Dose 3
4.5 g of omega-3 supplement
Dietary Supplement: SPM Active

Supplement or placebo will be administered orally between 9 am to 9:30 am.

  • Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.




Primary Outcome Measures :
  1. Regulation of peripheral blood pro-resolving mediator levels [ Time Frame: compared to baseline ]
    The Primary endpoint of the study will be an increase in peripheral blood SPM levels that will be measured using established liquid chromatography tandem mass spectrometry based approach


Secondary Outcome Measures :
  1. Regulation of bacterial phagocytosis by peripheral blood leukocytes [ Time Frame: compared to baseline ]
    An increase in ex vivo phagocytosis of Escherichia coli by peripheral white blood cells

  2. Regulation of peripheral blood platelet and leukocyte responses [ Time Frame: compared to baseline ]
    A decrease in white blood cell activation when cells are incubated with an inflammatory stimulus



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • For participants to be included in the study they will need to meet the following criteria:

    1. Able to provide informed consent
    2. Men and women between the age of 18 and 45
    3. Declare not to be taking aspirin, other NSAIDS, other form of medication or omega-3 fatty acid supplements for more than 2 weeks prior to screening and the duration of the participation.
    4. Willingness to abstain from eating fish for 2 days before each study visit
    5. Willingness to abstain from alcohol consumption for at least 24h prior to each study visit
    6. Willingness to abstain from caffeine as directed before and during study

Exclusion Criteria:

  • 1) History of, chronic disorders, cardiovascular disease (e.g., heart disease, stroke), cancer, or diabetes or significant genetically inherited conditions.

    2) Pregnancy or breast-feeding. 3) Hypothyroidism in the opinion of the investigator. 4) Liver disease in the opinion of the investigator. 5) Any abnormality or pre-existing disease which, in the opinion of the investigator, might either expose the subject to risk, or influence the validity of the results.

    6) Women of childbearing potential not taking adequate methods of contraception 7) Inability to read and write in English 8) Participation in a clinical study of a new chemical entity, biological product or a prescription medicine, or loss of more than 400 mL blood, within the previous 3 months 9) Anyone who is currently smoking or used to smoke 10) Presence or history of drug or alcohol abuse or intake of more than the amount of alcohol in the current guidelines on alcohol consumption


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03347006


Locations
United Kingdom
Queen Mary University of London
London, United Kingdom, EC1M 6BQ
Sponsors and Collaborators
Queen Mary University of London
Metagenics, Inc.

Responsible Party: Queen Mary University of London
ClinicalTrials.gov Identifier: NCT03347006     History of Changes
Other Study ID Numbers: 011549
16/LO/2182 ( Other Identifier: Research ethics council )
First Posted: November 20, 2017    Key Record Dates
Last Update Posted: June 11, 2018
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes